RAC 2.92% $1.94 race oncology ltd

Ann: Preclinical & Clinical Programs Update, page-18

  1. 2,658 Posts.
    lightbulb Created with Sketch. 2793
    the announcement got me thinking what is actually being patented for Pd-1 combo. Would it be

    1. Combo of pd-1 and Zantrene
    2. Combo of pd-1 and FTO inhibitor
    3. Both of the above for treatment (synergy)
    4. All of the above to overcome resistance?
    5. All of the above + cardio protect

    More so thinking, whether it is only the Zantrene molecule and analogies are protected. Or if the FTO pd-1 resistance process could be protected.

    just wondering, Apart from the obvious response that it won’t matter as Zantrene will be sold in 2-3 years?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.